In the 1970s, an unknown virus was suspected for documented cases of transfusion-
associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious …

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC),
with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one …

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …

Emerging studies have suggested that the Hippo pathway is involved in the tumorigenesis of
hepatocellular carcinoma (HCC). However, the key regulator of the Hippo pathway in liver …

Background: Rapid improvements in hepatitis C virus (HCV) therapy have led to the
approval of multiple oral direct-acting antiviral (DAA) regimens by the US Food and Drug …

Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …

Hepatitis C virus (HCV) is a hepatotropic RNA virus that causes progressive liver damage,
which might result in liver cirrhosis and hepatocellular carcinoma. Globally, between 64 and …

Recognizing the importance of timely guidance regarding the rapidly evolving field of
hepatitis C management, the American Association for the Study of Liver Diseases (AASLD) …

Background & Aims The success of direct-acting antivirals (DAA) against hepatitis C is a
major breakthrough in hepatology. Until now, however, there are very few data on the effect …

Background & Aims Concurrent to development of more effective drugs for treatment of
hepatitis C virus (HCV) infection, there has been an increase in the incidence of …